Nov 16 (Reuters) - Sanofi's irregular heart beat drug Multaq will no longer be reimbursed by the French health system from December, in a further setback to a medicine once seen as a blockbuster product.
The decision follows a July recommendation by France's top medical authority, the Haute Autorite de Sante, that Multaq should be withdrawn from the list of drugs reimbursed by the state-run health system.
HAS said at the time Multaq, known chemically as dronedarone, was not sufficiently effective.
Reimbursement in France will stop from Dec. 1, 2011, according to a notice published in the government's official bulletin.
Thursday, November 17, 2011
Sanofi's Multaq will no longer be reimbursed in France | Reuters